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Abstract
Background: Mycobacterium tuberculosis kills approximately 2 million people each year and presents an urgent need to
identify new targets and new antitubercular drugs. Thymidylate synthase (TS) enzymes from other species offer good
targets for drug development and the M. tuberculosis genome contains two putative TS enzymes, a conventional ThyA and
a flavin-based ThyX. In M. tuberculosis, both TS enzymes have been implicated as essential for growth, either based on drug-
resistance studies or genome-wide mutagenesis screens. To facilitate future small molecule inhibitors against these
proteins, a detailed enzymatic characterization was necessary.
Methodology/Principal Findings: After cloning, overexpression, and purification, the thymidylate-synthesizing ability of
ThyA and ThyX gene products were directly confirmed by HPLC analysis of reaction products and substrate saturation
kinetics were established. 5-Fluoro-29-deoxyuridine 59-monophosphate (FdUMP) was a potent inhibitor of both ThyA and
ThyX, offering important clues to double-targeting strategies. In contrast, the folate-based 1843U89 was a potent inhibitor
of ThyA but not ThyX suggesting that it should be possible to find ThyX-specific antifolates. A turnover-dependent kinetic
assay, combined with the active-site titration approach of Ackermann and Potter, revealed that both M. tuberculosis
enzymes had very low kcat values. One possible explanation for the low catalytic activity of M. tuberculosis ThyX is that its
true biological substrates remain to be identified. Alternatively, this slow-growing pathogen, with low demands for TMP,
may have evolved to down-regulate TS activities by altering the turnover rate of individual enzyme molecules, perhaps to
preserve total protein quantities for other purposes. In many organisms, TS is often used as a part of larger complexes of
macromolecules that control replication and DNA repair.
Conclusions/Significance: Thus, the present enzymatic characterization of ThyA and ThyX from M. tuberculosis provides a
framework for future development of cell-active inhibitors and the biological roles of these TS enzymes in M. tuberculosis.
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Introduction
An estimated 2 million deaths occur annually due to infections
of Mycobacterium tuberculosis, the causative agent of tuberculosis [1].
Multidrug-resistant tuberculosis, the recently discovered exten-
sively drug-resistant form of the disease, and the numerous side
effects of current drugs during the long course of drug treatment
are ongoing problems [2–4]. Rifampicin, the newest first line
antitubercular drug was introduced nearly 45 years ago [5].
Consequently there is an urgent need for identifying new drug
targets and inhibitors that can effectively combat this disease.
In other human diseases, the enzyme thymidylate synthase
(ThyA) is an attractive target for drug development [6]. ThyA
catalyzes the reductive methylation of 29-deoxyuridine-59-mono-
phosphate (dUMP) to thymidine-59-monophosphate (TMP) while
utilizing N
5,N
10-methylene-5,6,7,8-tetrahydrofolate (mTHF) as the
methyl donor and reductant in the reaction, yielding dihydrofolate
(DHF) as a by-product (Fig. 1A) [7]. Even partial inhibition of
ThyA causes an accumulation of 29-deoxyuridine-59-triphosphate
(dUTP) and a cascade of events leading to ‘‘thymine-less’’ cell
death [8,9]. Many established and experimental anticancer drugs,
such as 5-fluorouracil, Nolatrexed (AG337), Pemetrexed, and
Raltitrexed (ZD1694), act through this enzyme [10]. Prior
understanding of this general target in pharmacology, along with
the vast number of potent lead inhibitors already available, should
facilitate drug development against other indications including
antibacterials [11]. It has recently been postulated that p-
aminosalicylic acid, a commonly used antitubercular drug,
involves M. tuberculosis ThyA, suggesting that inhibition of ThyA
activity may be detrimental to M. tuberculosis growth and survival
[12]. The M. tuberculosis genome sequence also lacks thymidine
kinase, underscoring the essentiality of de novo TMP synthesis in
this pathogen [13]. On this basis, selective inhibition of M.
tuberculosis growth by ThyA inhibitors might not even require
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2237inhibitors selective for M. tuberculosis ThyA, as shown for the
experimental treatment of malaria by inhibition of ThyA [14,15].
In addition to the conventional ThyA, M. tuberculosis also
appears to carry a flavin-dependent thymidylate synthase (FDTS
or ThyX) [16]. Based on sequence and structural similarities to
related enzymes in Helicobacter pylori and Thermotoga maritima, M.
tuberculosis ThyX is expected to catalyze the reductive methylation
of dUMP to afford TMP using mTHF as the methyl donor in the
reaction (Fig. 1B) [13,16,17]. In other species, ThyX utilizes
NADPH and a bound FAD chromophore as the reductant for the
reaction. Indeed, crystal structure and sequence analysis have
found that M. tuberculosis ThyX binds NADP
+ and FAD and has
no direct similarity to ThyA [13]. In addition, site directed
mutagenesis studies have identified several amino acid residues,
including a conserved ‘‘ThyX motif’’ that are necessary for M.
tuberculosis ThyX tritium-release activity [18]. Direct confirmation
of full thymidylate synthase activity and its kinetic properties are
still necessary because of the low sequence homology of the ThyX
family of enzymes across species [13]. There is pharmacological
interest in this enzyme because the thyX gene is absent in humans
and transposon site hybridization (TraSH) experiments indicate
that Mycobacterium thyX is an essential gene for optimal growth of
the pathogen [19,20].
Despite the genomic, crystallographic, and mutagenesis studies,
many of the fundamental enzymatic properties, such as the
substrate and inhibitor binding abilities, of M. tuberculosis ThyA
and ThyX remain unknown. Understanding the biochemistry of
these enzymes is a necessary foundation needed for prioritizing
drug development strategies and assigning biological function with
confidence. In this study, we report on the expression, purification,
kinetic properties, and inhibitor-binding preferences of both M.
tuberculosis ThyA and ThyX. While the kinetic constants for
substrate binding are not unusual, both enzymes had surprisingly
low turnover rates. This evolutionary strategy raises important
questions about possible alternate or additional roles of these
enzymes in microbial functions. Regarding drug development,
given that individual cell types may be specifically targeted using
selective transport and selective drug activation properties of the
cell, our initial results suggest that fluorinated pyrimidines may be
used to inhibit both thymidylate synthase enzymes simultaneously.
In contrast different folate analogues may be customized to
selectively inhibit one enzyme over another.
Results and Discussion
Expression and purification
Histidine-tagged M. tuberculosis ThyA was overexpressed from
BL21(DE3) pLysS E. coli. Purification by nickel affinity, ion-
exchange, and size exclusion chromatography afforded pure
protein (Fig. 2A). A total of 18.5 mg of pure protein was obtained
from 1 L of bacterial culture. Size exclusion chromatography
(Fig. 2B) suggested that the protein had an apparent mass of
57 kDa, which is within 10% of the predicted mass of a dimer
(61.4 kDa). This is the first purification of ThyA from Mycobacteria.
Similarly, histidine-tagged M. tuberculosis ThyX was overexpressed
from BL21(DE3) pLysS E. coli. Again, purification by nickel
affinity and ion-exchange chromatography afforded pure protein
(Fig. 2A). A total of 8 mg of pure protein was obtained from 1 L of
bacterial culture (more recent protein preparations have routinely
yielded 20 mg of ThyX per liter of culture). Size exclusion
chromatography (Fig. 2B) suggested that this protein had an
apparent mass of 104 kDa, which is within 10% of the predicted
mass of a tetramer (114.8 kDa). This agrees with the previously
reported crystal structure, which shows that the enzyme exists as a
tetramer when crystallized [16].
Lack of autologous RNA binding
Autologous RNA binding by the classical thymidylate synthase,
ThyA, can play an important role in pharmacology. Whether a
protein binds its own RNA, and whether the resulting autologous
translational inhibition can be reversed with enzyme inhibitors,
can be important contributing variables to species-specific drug
action [21,22]. Human and P. falciparum ThyA have been shown to
bind their cognate mRNA coding sequence and to inhibit their
own translation [21–23]. The mRNA binding abilities of M.
tuberculosis ThyA and ThyX were probed using a gel-shift assay
Figure 1. Different reaction complexities of ThyA and ThyX. (A) ThyA converts dUMP to TMP using mTHF as a cofactor. mTHF is regenerated
by dihydrofolate reductase (DHFR) and serine hydroxymethyltransferase (SHMT). (B) ThyX converts dUMP to TMP using mTHF, NADPH, and FAD as
cofactors. mTHF is regenerated by SHMT.
doi:10.1371/journal.pone.0002237.g001
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mRNA. These initial results suggest that the expression levels of
M. tuberculosis ThyA and ThyX are not regulated by classic
autologous translational feedback loops and instead may be
dominated by regulation of RNA transcription.
Activity and substrate binding
The thymidylate-synthesizing abilities of M. tuberculosis ThyA
and ThyX were confirmed by reversed phase HPLC (Fig. 4). The
products of the enzymatic reactions were loaded onto a C18
column and decreases in dUMP and increases in TMP were
confirmed using known standards. This simple experiment was
necessary, particularly for ThyX. ThyA genes are very highly
conserved across species [11]. M. tuberculosis ThyA and the well
studied human ThyA (PDB # 1HZW) have a 53% sequence
identity, including several essential catalytic residues [7,24], thus
creating high confidence that M. tuberculosis ThyA would indeed
catalyze synthesis of thymidylate. In contrast, while the M.
tuberculosis thyX gene product contains certain sequence motifs and
structural elements identifying it as a TS [16], overall homology
between ThyX sequences is low [13] and there was no direct proof
of its ability to synthesize thymidylate.
Thymidylate synthase activities of the isolated proteins were also
verified using a tritium-release assay which depends on deprotona-
tion at the 5-position of the pyrimidine ring. ThyA and ThyX
produced 210 nmol and 9 nmol of tritiated water per minute per
mg of protein, respectively (Table 1). ThyX activity was also
verified by NADPH oxidation assay (data not shown). To examine
substrate binding, the purified enzymes were assayed with
increasing concentrations of either dUMP or mTHF, with varying
concentrations of the second substrate. Similarly, ThyX was
assayed with NADPH, with varying dUMP or mTHF. The
enzymes displayed standard Michaelis-Menten curves for all
substrates tested (Fig. 5 and 6). Fitting of the data to the
appropriate equation revealed Km values of 460.7 mM for dUMP
and 70630 mM for mTHF for M. tuberculosis ThyA (Table 2).
These values are similar to the experimentally determined values
for human ThyA (1.8 or 2.5 mM for dUMP and 12 or 31 mM for
mTHF) [25,26]. The kinetic constants calculated for M. tuberculosis
ThyX were 360.7 mM for dUMP, 4.061 mM for mTHF, and
47610 mM for NADPH (Table 2). These values were also similar
to experimentally determined values for other ThyX enzymes, 6–
65 mM for dUMP, 20–24 mM for mTHF, and 26 mM–4 mM for
NADPH [27–31].
Inhibitor binding
Many folate and nucleotide analogs target TS enzymes [10].
One interesting challenge in M. tuberculosis pharmacology is to
determine which compound class will inhibit which TS enzyme.
Inhibition of M. tuberculosis ThyA and ThyX by the potent
nucleotide-based inhibitor FdUMP, and the folate-based inhibitor
1843U89, were analyzed using the tritium-release assay. Based on
similarity between substrates and inhibitors, FdUMP was analyzed
Figure 2. Analysis of M. tuberculosis ThyA and ThyX by SDS-PAGE and size exclusion chromatography. (A) Purification of ThyA and ThyX
analyzed by SDS-PAGE (Lanes: 1, Molecular weight markers (see materials and methods); 2, 15 mg soluble lysate fraction; 3, 2 mg M. tuberculosis ThyA
after Ni
2+ column; 4, 2 mg M. tuberculosis ThyA after Q-sepharose column; 5, 2 mg M. tuberculosis ThyA after size exclusion; 6, Same as 1; 7, 15 mg
soluble lysate fraction from ThyX expression; 8, 2 mg M. tuberculosis ThyX after Ni
2+ column; 9, 2 mg M. tuberculosis ThyX after Q-sepharose column. (B)
Analysis of ThyA and ThyX by size exclusion chromatography. Protein standards (N) eluted at 47.79, 53.74, 59.69, 67.64, 72.62, 80.56, 94.80, and
102.65 mL (see materials and methods). ThyA (#) eluted at 84.35 mL. ThyX (%) eluted at 76.83 mL.
doi:10.1371/journal.pone.0002237.g002
Figure 3. RNA binding by M. tuberculosis ThyA and ThyX. M.
tuberculosis thymidylate synthases do not bind to their cognate mRNA.
0.35 nM of
32P labeled M. tuberculosis ThyX mRNA (lanes 1 and 2), M.
tuberculosis ThyA mRNA (lanes 3 and 4), or P. falciparum DHFR-TS mRNA
(lanes 5 and 6) was incubated in the presence or absence (lanes 1, 3,
and 5) of purified M. tuberculosis ThyX (3.5 mM, lane 2), M. tuberculosis
ThyA (3.5 mM, lane 4), or P. falciparum DHFR-TS (500 nM, lane 6).
Unbound RNA was digested with 3 units of RNase T1 prior to
electrophoresis [22].
doi:10.1371/journal.pone.0002237.g003
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mTHF. Titrating the enzyme with increasing concentrations of
substrate with various concentrations of the inhibitors revealed
standard Michaelis-Menten curves (Fig. 7 and 8). Fitting of the
data to the appropriate equation, based on double reciprocal plots,
provided the Ki values.
FdUMP inhibited both ThyA and ThyX (Table 2). While this
nucleotide-based inhibitor is a more potent inhibitor of ThyA (Ki,
2 nM), it still shows mid-nanomolar level inhibition of ThyX (Ki,
100 nM). This implies that fluorinated pyrimidine analogs could
be used to inhibit both enzymes simultaneously. Again, specificity
may be achieved from selection of appropriate fluorinated
Figure 4. HPLC analysis of M. tuberculosis ThyA and ThyX products. (A) M. tuberculosis ThyA reaction products. Based on absorbance at
260 nm, the peak corresponding to dUMP (tr=8.8 min) decreases while the peak corresponding to TMP (tr=11.1 min) increases over a 120 minute
time course (0, 30, 60, and 120 minute time points). (B) M. tuberculosis ThyX reaction products. The peak corresponding to dUMP (tr=8.8 min)
decreases while the peak corresponding to TMP (tr=11.1 min) increases over a 120 minute time course (0, 30, 60, and 120 minute time points).
doi:10.1371/journal.pone.0002237.g004
Figure 5. Steady-state kinetics of M. tuberculosis ThyA. (A) Titrations of mTHF (29, 143, 571, 1143 mM) with varying concentrations of dUMP (N,
1.875 mM; ., 3.75 mM; &, 7.5 mM; ¤,1 5mM). (B) Double reciprocal plot of data from plot A showing a sequential reaction mechanism. (C) Titrations
of dUMP (1.875 mM, 3.75 mM, 7.5 mM, 15 mM) with varying concentrations of mTHF (N,2 9mM; ., 143 mM; &, 571 mM; ¤, 1143 mM). (D) Double
reciprocal plot of data from plot C showing a sequential reaction mechanism. Lines in A and C are plots of Michaelis-Menten equations with
calculated constants. Lines in B and D are linear regressions. Error bars are propagation of standard deviations.
doi:10.1371/journal.pone.0002237.g005
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1.25 mM; ., 2.5 mM; &,5mM; ¤,1 0mM; m,2 0mM). (B) Double reciprocal plot of data from plot A showing a sequential reaction mechanism. (C)
Titrations of dUMP (1.25, 2.5, 5, 10, 20 mM) with varying concentrations of mTHF (N, 1.25 mM; ., 2.5 mM; &,5mM; ¤,1 0mM; m,2 0mM). (D) Double
reciprocal plot of data from plot C showing a sequential reaction mechanism. (E) Titrations of NADPH (12.5, 25, 50, 100, 200 mM) with varying
concentrations of mTHF (N, 1.25 mM; ., 2.5 mM; &,5mM; ¤,1 0mM; m,2 0mM) in the presence of 2.86 mM dUMP. (F) Double reciprocal plot of data
from plot E showing a sequential reaction mechanism. Lines in A, C, and E are plots of Michaelis-Menten equations with calculated constants. Lines in
B, D, and F are linear regressions. Error bars are propagation of standard deviations.
doi:10.1371/journal.pone.0002237.g006
Table 1. Purification of M. tuberculosis ThyA and ThyX.
Enzyme and Purification step
Total amount of
protein (mg)
Total activity
(nmol/min)
Sp. activity
(nmol/min/mg)
Purification
factor
Yield
(%)
M. tuberculosis ThyA
Cell lysate 490 18,620 38 1 100
Purified protein 18.5 3,885 210 5.5 21
M. tuberculosis ThyX
Cell lysate 340 782 2.3 1 100
Purified protein 8 72 9 4 9
doi:10.1371/journal.pone.0002237.t001
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[15,32,33].
While 1843U89 inhibited ThyA with a Ki of 18 nM, it
displaying a 600-fold weaker binding to ThyX (Table 2). This
compound was originally designed to inhibit human ThyA which
is very similar in amino acid sequence to M. tuberculosis ThyA and
quite dissimilar to M. tuberculosis ThyX. Just as 1843U89 is highly
selective for ThyA over ThyX, basic thermodynamic principles
suggest that reciprocal inhibitors for M. tuberculosis ThyX should
exist. Such is the case in the selective inhibition of P. falciparum
dihydroorotate dehydrogenase (DHODH) over human DHODH.
Initially, it was shown that common DHODH inhibitors were
approximately 2,000–5,000-fold selective for the human enzyme
over the P. falciparum enzyme [34]. A subsequent high-throughput
screen identified inhibitors up to 12,500-fold selective for P.
falciparum DHODH over human DHODH [35,36]. In addition to
implications for future drug development strategies, TS-selective
folate inhibitors should play an important role in untangling the
biological roles of these two enzymes in M. tuberculosis biology.
Low turnover
The present kinetic experiments revealed that M. tuberculosis
ThyA and ThyX have very low catalytic rates for the synthesis of
TMP. Initially, Vmax with known protein amounts in the reactions,
we obtained apparent kcat values of 6 min
21 and 0.25 min
21 for
ThyA and ThyX respectively. To rule out potential artifacts due to
misfolded or inactive protein, the method of Ackermann and
Potter was applied to determine the absolute kcat values of
catalytically active ThyA and ThyX protein molecules [37–39].
Activity was determined with varying amounts of the purified
enzymes titrated with increasing concentrations of FdUMP (Fig. 9).
The slopes from the primary and secondary Ackermann-Potter
plots revealed a kcat value of 18 min
21 for M. tuberculosis ThyA.
This is still an order of magnitude lower than the values for human
and P. falciparum ThyA (150 min
21 and 120 min
21, respectively
[26,40]). The rate of turnover by M. tuberculosis ThyX was even
slower, with a kcat value of 0.4 min
21. This too was determined
using the Ackermann-Potter method. Of all the ThyX enzymes
studied from other microorganisms, which show as much as 100-
fold variations in specific activity for ThyX [27,28,30,31], the M.
tuberculosis ThyX enzyme is the slowest. The ThyA and ThyX
turnover numbers raise some important biological questions
relevant to TB pharmacology. Due to the low turnover rates of
ThyX enzymes in general, several studies have questioned whether
the true biological substrates for this enzyme have been identified
[31,41,42]. While the substrates used in the present work were
able to catalyze turnover in vitro, it is possible that they do not
provide an accurate measure of in vivo activity. Alternatively, the
low turnover rate may be related to an important evolutionary
characteristic of M. tuberculosis. It is a very slow growing pathogen,
presumably with limited needs for TMP. Normally, one would
assume that such an organism would evolve to down-regulate
thymidylate synthesizing protein expression, compared to rapidly
proliferating cells. The present chemical data raises the possibility
that this slow-growing pathogen may have evolved to decrease the
catalytic activity of individual enzyme molecules, perhaps to
preserve total protein quantities for other purposes. Cellular role of
TS proteins can extend beyond generating TMP. ThyA is often
found as a part of a larger complex of proteins and RNA that are
involved in control of cell replication as well as DNA repair [43]. If
ThyA levels and ThyX levels are not low, development of
pathogen inhibitors will have to rely on selectivity mechanism
other than low target levels.
Concluding remarks
The present chemical studies help to set the initial foundation to
further evaluate M. tuberculosis ThyA and ThyX as chemothera-
peutic targets against tuberculosis. Even though M. tuberculosis
carries two genes for thymidylate synthesis, both of which have
been implicated as important in growth and survival of this major
human pathogen, the biological data available to date do not
define the detailed metabolic role and the vulnerability of M.
tuberculosis to inhibitors of these enzymes. If detailed genetic
manipulations of individual genes formally show that both genes
are essential, chemical genetic approaches based on the present
enzymatic studies will follow. These should facilitate an under-
standing of whether target inhibition of one or both enzymes is
needed to kill M. tuberculosis in its growth phase, whether target
inhibition of one or both enzymes is needed to kill M. tuberculosis in
its latent phase, whether the bacteria can upregulate each of the
proteins in the presence of inhibitors to overcome drug action,
whether one gene can facilitate resistance to inhibitors directed at
the other TS, and whether selective dual targeting may be
required to successfully shut off TMP synthesis.
Materials and Methods
Reagents
FAD, NADPH, tetrahydrofolic acid, Pefabloc SC, DNAseI,
FdUMP, dUMP, TMP and protein standards for size-exclusion
chromatography were purchased from Sigma-Aldrich (St. Louis,
MO). [5-
3H]-dUMP was purchased from Moravek Biochemicals
(Brea, CA). His GraviTrap columns, DEAE Sepharose Fast Flow,
Q Sepharose Fast Flow, and Superdex 200 were purchased from
GE Healthcare (Piscataway, NJ). Protein concentrations were
measured using the Protein Assay kit from Bio-Rad Laboratories
(Hercules, CA). Low-range protein molecular weight markers were
obtained from Bio-Rad Laboratories (Hercules, CA) (phosphory-
lase b, 97,400; serum albumin, 66,200; ovalbumin, 45,000;
carbonic anhydrase, 31,000; trypsin inhibitor, 21,500; lysozyme,
14,400). The T7 Riboprope in vitro transcription system was
obtained from Promega (Madison, WI). RNasin and RNase T1
were purchased from Ambion (Foster City, CA). Uridine 59-
triphosphate [a-
32P] was purchased from American Radiolabeled
Chemicals (St. Louis, MO). To prepare a 20 mM stock solution of
methylene tetrahydrofolate (mTHF), solid tetrahydrofolic acid was
dissolved in a buffer containing 125 mM TES, 60 mM MgCl2,
2.5 mM EDTA (pH 8.0), 190 mM 2-mercaptoethanol, and
Table 2. Comparison of kinetics of Human ThyA to M.
tuberculosis ThyA and ThyX.
Km (mM) Ki (nM)
Enzyme dUMP mTHF NADPH
kcat
(min
21) FdUMP 1843U89
M. tuberculosis
ThyA 460.7 70630 - 18 260.2 1861.0
ThyX 360.7 4614 7 610 0.4 100610 11,2006900
Human
ThyA 2.5
a,1 . 8
b 12
a,3 1
b -1 5 0
c 1.7
b 0.09
d
aFrom Dev et al. [46].
bFrom Dolnick and Cheng [25].
cFrom Davisson et al. [26].
dFrom Pendergast et al. [44].
doi:10.1371/journal.pone.0002237.t002
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made from this stock solution. mTHF solutions were stored under
argon at 220uC. 1843U89 was synthesized as previously reported
[44].
Expression and purification of M. tuberculosis ThyA
The thyA gene was cloned from a pET24d(+) vector with a C-
terminal His-Tag into a pET23d(+) vector with an N-terminal His-
Tag using the forward primer (TTA CCA GCT AGC CTC GAG
ATG CAC CAC CAC CAC CAC CAC ACG CCA TAC GAG
GAC CTG CTG) and the reverse primer (GTT ATT GAG CTC
CCC GGG TCA TAC CGC GAC TGG AGC TTT GAT C)
including NheI and SacI restriction sites (underlined) and the
plasmid construct was confirmed by sequencing. The protein was
expressed in BL21(DE3) pLysS E. coli in 100 mL LB media
containing 50 mg/mL ampicillin and 35 mg/mL chloramphenicol
at 37uC overnight. About 50 mL of the overnight culture was
added to 1 L of LB with the appropriate antibiotics. The 1 L
culture was grown to an OD600 nm of 0.6 and IPTG was added to
give a final IPTG concentration of 1 mM. After 6 hours, the cells
were harvested by centrifugation at 10,0006ga t4 uC and the cells
were resuspended, on ice, in 20 mM sodium phosphate (pH 7.4),
500 mM sodium chloride, 15 mM magnesium chloride, 20 mM
imidazole, 20 mg/mL DNAseI, 1 mM Pefabloc SC, and 0.2 mg/
mL lysozyme and lysed by sonication. Cell debris was removed by
centrifugation at 10,0006ga t4 uC and the cleared lysate was
purified on a His GraviTrap column as specified by the
manufacturer. The crudely purified protein was dialyzed against
75 mM potassium phosphate (pH 7.8), 0.1 mM EDTA, and
1 mM DTT and bound to a DEAE Sepharose Fast Flow column.
The protein was eluted with a 0–250 mM NaCl gradient.
Fractions containing ThyA were pooled, concentrated, and
purified on a Superdex 200 size exclusion column with elution
by 20 mM Tris (pH 7.8), 150 mM KCl, 1 mM DTT, and
0.1 mM EDTA. The enzyme was frozen at 220uC in the same
buffer containing 20% glycerol.
Expression and purification of M. tuberculosis ThyX
The gene for M. tuberculosis thyX with a C-terminal His-Tag was
expressed as above [16]. ThyX bound the Ni
2+ column tightly and
was eluted with 20 mM sodium phosphate (pH 7.4), 1M NaCl,
and 1M imidazole. The crudely purified protein was dialyzed,
against 10 mM Tris HCl (pH 7.2), 50 mM NaCl, and 2 mM
DTT, and bound to a Q Sepharose Fast Flow column. The
protein was eluted with a 50–500 mM NaCl gradient. Fractions
containing ThyX were pooled, dialyzed against 50 mM Tris HCl
(pH 7.5), 200 mM NaCl, and 10% glycerol, and frozen at 220uC.
Protein size
The approximate masses of ThyA and ThyX, in solution, were
determined using size-exclusion chromatography. A mixture of
protein standards consisting of: Blue Dextran (void volume
marker), thyroglobulin (669 kDa), apoferritin (443 kDa), b-amy-
lase (200 kDa), alcohol dehydrogenase (150 kDa), bovine serum
Figure 7. Inhibition of M. tuberculosis ThyA by 1843U89 and FdUMP. (A) Titrations of mTHF (50, 150, 300, 600, 1200 mM) with varying
concentrations of 1843U89 (N, 0 nM; ., 12.5 nM; &, 25 nM; ¤, 50 nM; m, 75 nM) in the presence of 3.75 mM dUMP. (B) Double reciprocal plot of data
from plot A showing a noncompetitive inhibition mechanism. (C) Titrations of dUMP (1.25, 2.5, 5, 10 mM) with varying concentrations of FdUMP (N,
0 nM; ., 2.5 nM; &, 5 nM; ¤, 10 nM) in the presence of 142.9 mM mTHF. (D) Double reciprocal plot of data from plot C showing a noncompetitive
inhibition mechanism. Lines in A and C are plots of Michaelis-Menten equations with calculated constants. Lines in B and D are linear regressions.
Error bars are propagation of standard deviations.
doi:10.1371/journal.pone.0002237.g007
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C (12.4 kDa), was loaded onto a Superdex 200 size-exclusion
column with a bed volume of 120 mL (the concentration of the
standards was 1–2 mg/mL for each protein). The standards were
eluted with 20 mM potassium phosphate (pH 7.8), 150 mM KCl,
1 mM DTT, and 0.1 mM EDTA with a flow rate of 0.7 mL/min.
Samples of ThyA and ThyX were loaded onto the column at a
concentration of approximately 1.5 mg/mL and eluted with the
same buffer and flow rate. A plot of elution volume/void volume
versus log of the molecular weight standards gave a linear data set
whose regression line was used to calculate thymidylate synthase
molecular weight from enzyme elution volumes [45].
RNA binding assay
RNA binding experiments was measured as previously
described [21,22]. ThyA and ThyX mRNA was generated using
the T7 Riboprobe in vitro transcription system (Promega) following
the manufacturers protocol. The RNA was purified by phenol/
chloroform extraction followed by ethanol precipitation. The
amount of RNA transcribed was determined by measuring the
OD260 nm of the solution. Electrophoresis using 1% formamide
agarose was used to determine the size and integrity of the RNA.
Radiolabeled RNA was made by using 12 mM rUTP and adding
50 mCi of [a-
32P] UTP. Labeled RNA was quantified by the
32P-
incorporation assay following the protocol from Promega. RNA
(0.35 nM labeled with 100,000 cpm
32P) was incubated with
varying concentrations of purified enzyme in 10 mM HEPES
pH 7.5, 3 mM MgCl2, 40 mM KCl, 5% glycerol, 200 mM 2-
mercaptoethanol, and 1 unit of RNasin at 37uC for 15 minutes.
The unbound RNA was digested by addition of 3 units of RNase
T1 and incubation at 25uC for 10 minutes. Non-specific
interactions were reduced by addition of 5 mg/ml heparin and
incubation at 25uC for 10 minutes. The RNA-protein complexes
were resolved on a 5% TBE polyacrylamide gel and visualized by
autoradiography.
TMP synthesis
Approximately 150 ng of M. tuberculosis ThyA, or 3 mgo fM.
tuberculosis ThyX, was added to a mixture of 60 mL mTHF (final
mTHF concentrations were 143 mM for ThyA assay or 20 mM for
ThyX assay), 15 mL of 140 mM dUMP, 3 mL of 350 mM FAD (for
ThyX assay only), and 1 mL of 35 mM NADPH (for ThyX assay
only) and water to give reaction volume of 105 mL. The reaction
times varied from 30 to 120 minutes. To isolate the products, the
reaction mixture was spun through a Microcon YM-10 centrifugal
filter (MWCO=10,000) at 13,0006g for 5 minutes. An additional
100 mL of water was added and the spin was repeated. The
deproteinized reaction mixture was run on an HPLC using a
Beckman reversed phase Ultrasphere ODS 5 mm C-18 column
(4.6 mm ID, 150 mm length) with isocratic flow with 5 mM
potassium phosphate (pH 7.0), 5 mM tetrabutylammonium dihy-
drogen phosphate, and 5% (v/v) acetonitrile, while monitoring
Figure 8. Inhibition of M. tuberculosis ThyX by 1843U89 and FdUMP. (A) Titrations of mTHF (1.25, 2.5, 10, 20 mM) with varying concentrations
of 1843U89 (N,0mM; .,2 5mM; &,5 0mM; ¤, 100 mM; m, 400 mM) in the presence of 2.86 mM dUMP. (B) Double reciprocal plot of data from plot A
showing a noncompetitive inhibition mechanism. (C) Titrations of dUMP (1.25, 2.5, 5, 7.5, 10 mM) with varying concentrations of FdUMP (N, 0 nM; .,
250 nM; &, 500 nM; ¤, 750 nM; m, 1000 nM) in the presence of 8 mM mTHF. (D) Double reciprocal plot of data from plot C showing a mixed
inhibition mechanism. Lines in A and C are plots of Michaelis-Menten equations with calculated constants. Lines in B and D are linear regressions.
Error bars are propagation of standard deviations.
doi:10.1371/journal.pone.0002237.g008
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mTHF were also run to assign the elution positions of reactants
and products.
Thymidylate synthase assay
In a standard tritium-release assay, 50 ng of M. tuberculosis ThyA
or 1 mgo fM. tuberculosis ThyX, in 1 mL, was added to 20 mL
mTHF (mTHF concentrations in the reactions ranged from
5.7 mM–1143 mM for ThyA assay or 1.25 mM–20 mM for ThyX
assay), 1 mL of 200 mM FAD (for ThyX assay only), and 1 mLo f
2 mM NADPH (for ThyX assay only). The total reaction volume
was brought to 30 mL with the addition of water. To initiate the
reaction, 5 mL of 13.1 mM–140 mM [5-
3H]-dUMP (0.4 Ci/mmol)
was added. After a 25 minute reaction period, at room
temperature, the reaction was terminated by the addition of
20 mL of a stop solution (a 3:1 ratio of 2 N TCA:4.3 mM dUMP).
To remove unreacted substrates, 200 mL 10% (w/v) activated
charcoal in water was added to the reaction mixture. The reaction
tubes were incubated on ice for 15 minutes then spun at 13,0006g
at 4uC for 10 minutes. A 100 mL aliquot of the supernatant was
assayed by liquid scintillation counting to determine the amount of
tritium-containing water produced by the reaction. Specific
activities and Vmax values were determined in the presence of
saturating concentrations of substrates.
Kinetic properties
The tritium release, at fixed time points, revealed initial reaction
velocities needed to calculate the Km values of dUMP, mTHF, and
NADPH and the kcat values of thymidylate synthase activity. See
the legends for Fig. 5, 6, and 9 for substrate concentrations. Plots
of reaction velocity (v) versus substrate concentration (A and/or B)
were fit, using SigmaPlot 9.0, to the Michaelis-Menten equation
for a sequential mechanism: v=(Vmax[A][B])/([A][B]+Km
A[B]+
Km
B[A]+Km
BKs
A). kcat values were determined from Ackermann-
Potter plots using the equation, Slope=(kcat[S])/([S]+Km) [37–39].
See the legend for Fig. 9 for enzyme and inhibitor concentrations.
Inhibitory constants
The tritium-release assay was also used to determine the Ki
values of the inhibitors for the ThyA and ThyX enzymes. Inhibitor
and corresponding substrate concentrations were varied as listed in
the legends of Fig. 7 and 8 (dUMP was varied against changing
FdUMP in the reactions and mTHF was varied against changing
1843U89 in the reactions). The data yielded double reciprocal
plots that were fit to linear regression lines. Plots of reaction
velocity versus substrate concentration were fit, using SigmaPlot
9.0, to the appropriate Michaelis-Menten equation for an
inhibition by a non-competitive: v=(Vmax[B])/((1+[I]/
Ki)(Km
B+[B])), competitive: v=(Vmax[B])/(Km
B(1+[I]/Ki+[B]), or
mixed inhibitor: v=(Vmax[B])/(Ks
A(1+[I]/Ki)+[B](1+[I]/Kis)).
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